Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive ...
FierceBiotech

Recursion lines up $50M Nvidia collab for AI-powered drug discovery

Through the funding and collaboration with Nvidia, Recursion plans to develop new AI models for drug discovery on the Nvidia DGX Cloud—billed as “AI-training-as-a-service” software. (iambuff/ ...
TMCnet

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model

Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new ...
C&EN

Recursion to buy AI rival Exscientia

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
GEN

Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine

While Recursion incurred higher operating costs for R&D and general and administrative activities, the company also received from Roche and Genentech a $30 million “acceptance fee” for the completion ...